Overview

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Status:
Suspended

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.

Phase:

Phase 2

Details

Lead Sponsor:

University of Florida

Collaborators:

GlaxoSmithKline
Tesaro, Inc.

Treatments:

Niraparib
Poly(ADP-ribose) Polymerase Inhibitors